Emerging roles for phospholipase A2 enzymes in cancer

Biochimie

Volumn 92, Issue 6, 2010, Pages 601-610

  Scott, Kieran F ^a   Sajinovic, Mila ^a,c   Hein, Juliane ^c   Nixdorf, Sheri ^c   Galettis, Peter ^d   Liauw, Winston ^d   de Souza, Paul ^d   Dong, Qihan ^e   Graham, Garry G ^a   Russell, Pamela J ^b,c,f,g  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f Translational Research Institute   (Australia)

^g QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Arachidonic acid; Cancer; Eicosanoid; Neoplasm; Phospholipase A2; Prostaglandins; Prostate; Tumour

Indexed keywords

PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP IB; PHOSPHOLIPASE A2 GROUP IIA; PHOSPHOLIPASE A2 GROUP IID; PHOSPHOLIPASE A2 GROUP IIE; PHOSPHOLIPASE A2 GROUP IIF; PHOSPHOLIPASE A2 GROUP III; PHOSPHOLIPASE A2 GROUP IV; PHOSPHOLIPASE A2 GROUP IVA; PHOSPHOLIPASE A2 GROUP V; PHOSPHOLIPASE A2 GROUP VII; PHOSPHOLIPASE A2 GROUP X; SECRETORY PHOSPHOLIPASE A2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; COLON CANCER; GENE DELETION; GENE MUTATION; HUMAN; LUNG CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STOMACH CANCER;

ANIMALS; CELL PROLIFERATION; HUMANS; INFLAMMATION; MICE; NEOPLASMS; PHOSPHOLIPASES A2;

MUS;

EID: 77953286792     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.03.019     Document Type: Review

References (91)

1. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
2. Suter C.M., Martin D.I., Ward R.L. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 2004, 36:497-501.
3. Barabasi A.-L., Oltavai Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 2004, 5:101-113.
4. Barabasi A.-L. Scale-free networks: a decade and beyond. Science 2009, 325:412-413.
5. Bucyzynski M.W., Dumlao D.S., Dennis E.A. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 2009, 50:1015-1038.
6. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
7. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
8. Moreno J.J. New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and development. Biochem. Pharmacol. 2009, 77:1-10.
9. Wang D., DuBois R.N. Prostaglandins and cancer. Gut 2006, 55:115-122.
10. Fürstenberger G., Krieg K., Müller-Decker K., Hebenicht A.J.R. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?. Int. J. Cancer 2006, 119:2247-2254.
11. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of conlorectal cancer. JAMA 2009, 302:649-658.
12. 2 superfamily and its group numbering system. Biochim. Biophys. Acta 2006, 1761:1246-1259.
13. 2 expression in tumours: a target for therapeutic intervention?. Drug Discov. Today 2003, 8:710-716.
14. 2 as targets for anti-cancer drugs. Biochem. Pharmacol. 2007, 74:949-959.
15. 2. Annu. Rev. Biochem. 2008, 77:495-520.
16. 2 family. Prog. Lipid Res. 2006, 45:487-510.
17. 2: homeostatic phospholipases with significant potential as tragets for novel therapeuticss. Curr. Drug Targets 2008, 9:683-689.
18. 2 in patients with various malignant tumours. Enzyme 1990, 43:80-88.
19. 2) in pancreatic diseases. Gastroenterol. Jpn. 1991, 26:62-68.
20. 2 in inflammatory disease. Clin. Chem. 1993, 39:2453-2549.
21. 2 enzymes as therapeutic targets. Expert Opin. Ther. Targets 2003, 7:427-440.
22. 2. Front. Biosci. 2008, 13:1917-1925.
23. 2 levels in patients with infections after Esophageal cancer surgery. Surg. Today 2005, 35:912-918.
24. 2 increases with prostate tumor grade. Clin. Cancer Res. 2001, 7:3857-3861.
25. 2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastisis. Proc. Natl. Acad. Sci. USA 2002, 99:16203-16208.
26. 2-III as a biomarker candidate. Br. J. Cancer 2008, 98:587-595.
27. 2 in human colorectal adenocarcinoma. Cancer Lett. 2002, 182:175-182.
28. 2 isofprms in advanced stage ovarian carcinoma. Gynecol. Oncol. 2006, 103:831-840.
29. Smith M.W., Yue Z.N., Geis G.K., et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res. 2003, 63:859-864.
30. 2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am. J. Pathol. 2002, 160:667-671.
31. Nagy R., Sweet K., Eng C. Highly penetrant hereditary cancer syndromes. Oncogene 2004, 23:6445-6470.
32. 2 gene is a candidate for the Mom1 Locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995, 81:957-966.
33. Cormier R.T., Hong K.H., Halberg R.B., et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 1999, 17:88-91.
34. Nimmrich I., Friedl W., Kruse R., et al. Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patient with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in pateints with FAP. Hum. Genet. 1997, 100:345-349.
35. Praml C., Amler L.C., Dihlmann S., Finke L.H., Schlag P., Schwab M. Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa. Oncogene 1998, 17:2009-2012.
36. 2 gene alterations in human colorectal cancer. Cancer Res. 1995, 55:5184-5186.
37. Spirio L.N., Kutchera W., Winstead M.V., et al. Three secretory phospholipase A(2) genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli. Cancer Res. 1996, 56:955-958.
38. 2 mutations in neuroblastoma, melanoma and colon cancer cell lines. Int. J. Cancer 1997, 72:337-339.
39. Kennedy B.P., Soravia C., Moffat J., et al. Overexpression of nonpancreatic secretory groupII PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res. 1998, 58:500-503.
40. 2 in colon tumour cells potentiates tumor growth. Mol. Carcinog. 2007, 46:106-116.
41. 2 in prostate cancer. Cancer Res. 2004, 64:6934-6940.
42. Morgenbesser S.D., McLaren R.P., Richards B., et al. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate 2007, 67.
43. 2 in normal and malignant prostate cancer cell lines: regulation by cytokines, cell signalling pathways and epigentetic mechanisms. Neoplasia 2008, 10:279-286.
44. 2 stimulated the proliferation of colon cancer cells by producing various lipid mediators. Mol. Pharmacol. 2009, 76:778-790.
45. 2. J. Biol. Chem. 2005, 280:24987-24998.
46. 2 by oncogenic ras in human non-small cell lung cancer. J. Biol. Chem. 1997, 272:14501-14504.
47. 2 by oncogenic ras is mediated through the JNK and ERK Pathways in rat epithelial cells. J. Biol. Chem. 2001, 276:1226-1232.
48. 2. Carcinogenesis 2004, 25:1517-1524.
49. Takaku K., Sonoshita M., Sasaki N., et al. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J. Biol. Chem. 2000, 275:34013-34016.
50. 2 deletion enhmaces colon tumorigenesis. Cancer Res. 2005, 65:2636-2643.
51. 2 are produced in human pancreatic cancer cells and influence prognosis. Gut 1999, 45:605-612.
52. 2 production. Cancer Lett. 2006, 243:255-263.
53. 2 in premalignant and malignant Barrett's oesophagus. Virchows Arch. 2004, 426-435.
54. Patel M.I., Singh J., Niknami M., et al. Cytosolic phospholipase A2- a: a potential therapeutic target for prostate cancer. Clin. Cancer Res. 2008, 14:8070-8079.
55. 2 in activated cells. Cell. Signal. 2005, 17:1052-1062.
56. 2 induces a p53-dependent cell-cycle arrest in G1 phase. J. Cell Sci. 2006, 119:1005-1015.
57. 2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms. J. Pharmacol. Exp. Ther. 2008, 326:59-68.
58. 2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem. J. 2007, 406:427-436.
59. 2 in cell growth and signalling. Biochem. Pharmacol. 2008, 76:1059-1067.
60. 2 through arachidonic acid mobilization, is involved in Caco-2 cell growth. J. Cell Physiol. 2002, 193:293-298.
61. 2. J. Biol. Chem. 1998, 273:14411-14423.
62. 2s and cyclooxygenase in immediate and delayed prostaglandin biosynthetic pathways. J. Biol. Chem. 1999, 274:3103-3115.
63. 2. J. Biol. Chem. 2005, 280:14028-14041.
64. 2 in human cancer cells: implications in apoptosis resistance. Exp. Cell Res. 2005, 306:75-84.
65. 2b. Biochemistry 2004, 43.
66. 2 (iPLA2b)-mediated ceramide generation plays a key role in the cross-talk between the endoplasmic reticulum and mitochondria during ER stress-induced insulin secreting cell apoptosis. J. Biol. Chem. 2008, 283:34819-34832.
67. 2 enhances cell migration in non-apoptotic ovarian cancer cells. J. Biol. Chem. 2006, 281:29357-29368.
68. Lauber K., Bohn E., Krober S.M., et al. Apoptotic cells induce migration of phagocytes via Caspase-s mediated release of a lipid attraction signal. Cell 2003, 113:717-730.
69. Smani T., Zakharov S.I., Csutora P., Leno E., Trepakova E.S., Bolotina V.M. A novel mechanism for the store operated calcium influx pathway. Nat. Cell Biol. 2004, 6:113-120.
70. Yang S., Zhang J.J., Huang X.-Y. Orai1 and STIM1 are critical for breast tumour cell migration and metastasis. Cancer Cell 2009, 15:124-134.
71. Bolotina V.M. Orai, STIM1 and iPLA2 b: a view from a different perspective. J. Physiol. 2008, 586:3035-3042.
72. 2+ channels with different activation modes and molecular origin in LNCaP human prostate cancer epithelial cells. J. Biol. Chem. 2004, 279:30326-30337.
73. Prevarskaya N., Skryma R., Bidaux G., Flourakis M., Shuba Y. Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ. 2007, 14.
74. 2 in prostate cancer. Cancer Lett. 2006, 240:9-16.
75. 2 levels in patients with advanced cancer. Clin. Chim. Acta 1994, 228:91-99.
76. 2 in human male reproductive organs and genital tumors. Prostate 1998, 35:263-272.
77. 2 as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. APMIS 2009, 117:151-161.
78. 2 shows malignant potential of human breast cancer cells. Cancer 1993, 71:3058-3064.
79. 2. Breast Cancer Res. Treat. 2008, 111:209-218.
80. Wendum D., Svreck M., Rigau V., et al. COX-2, inflammatory secreted PLA2 and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Mod. Pathol. 2003, 16:130-136.
81. Denizot Y., Chianea T., Labrousse F., Truffinet V., Delage M., Mathonnet M. Platelet-activating factor and human thyroid cancer. Eur. J. Endocrinol. 2005, 153:31-40.
82. Denizot Y., Gainant A., Guglielmi L., Bouvier S., Cubertafond P., Mathonnet M. Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients. Oncogene 2003, 22:7222-7224.
83. Denizot Y., Descottes B., Truffinet V., Valleix D., Labrousse F., Mathonnet M. Platelet-activating factor and liver metastasis of colorectal cancer. Int. J. Cancer 2004, 113:503-505.
84. 2 and platelet activating factor acetylhydrolase activity in colorectal cancer. Mediators Inflamm. 2004, 13:53-54.
85. Mathonnet M., Descottes B., Valleix D., Truffinet V., Labrousse F., Denizot Y. Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma. World J. Gastroenterol. 2006, 12:2773-2778.
86. Denizot Y., De Armast R., Caire F., Pommepuy I., Truffinet V., Labrousse F. Platelet activating factor and human meningiomas. Neuropathol. Appl. Neurobiol. 2006, 32.
87. Denizot Y., Desplat V., Drouet M., Bertin F., Melloni B. Is there a role for platelet activating factor in human lung cancer?. Lung Cancer 2001, 33:195-202.
88. 2 in the tumours and mucosa of the colon and rectum. EJSO 2001, 27.
89. 2) as a prognostic determinant of stage II colorectal carcinoma. Annals. Oncol. 2009, 20:1230-1235.
90. Imaizumi T., Satoh K., Yoshida H., et al. Activity of platelet -activating factor (PAF) acetylhydrolase in plasma from healthy habitual cigarette smokers. Heart Vessels 1990, 5:81-86.
91. 2 and fatty acids in human colon tumours and associated normal tissue. Eur. J. Cancer 1996, 32A:1781-1787.